Immunis Bio announced on the 24th that it has signed a contract with the Ministry of Health and Welfare of Uzbekistan to supply the NK cell therapy 'MYJ1633' for the treatment of pediatric leukemia.
The contract was signed at Immunis Bio's headquarters in Incheon. The agreement includes the supply of pediatric leukemia treatments and anticancer therapies, as well as cartilage progenitor cell therapies and stem cell therapies from its affiliate, Smart Cell Lab. The goal is to elevate Uzbekistan's standards in cell and gene therapy to a global level. This is expected to lay the foundation for the full-scale entry of Korean cell therapies into Uzbekistan. Over the next 10 years, it is anticipated that sales will exceed 300 billion KRW, further enhancing the status of Korean cell therapies in Central Asian countries.
The pediatric leukemia treatment initiative promoted by the Uzbekistan government is known to be a national agenda supported by the president and first lady, focusing on children who will be the pillars of future society. To find stable and effective treatments, the Ministry of Health and Welfare of Uzbekistan conducted comprehensive analysis and evaluation of global cell and gene therapies, selecting Immunis Bio's NK cell therapy as the most suitable treatment. Immunis Bio plans to establish a corporation and GMP facility in Uzbekistan in the second half of this year to begin full-scale production of therapies to treat children suffering from cancer.
The chief researcher at Immunis Bio stated, "Through the K-BIO support project backed by the government, we developed therapies with global competitiveness," adding, "Although we are a venture company, our technology was recognized and we secured a contract with the Uzbekistan government by surpassing world-class competitive technologies."
Immunis Bio CEO Kang Jeong-hwa explained, "We will expand not only pediatric leukemia treatments in Uzbekistan but also our cartilage and stem cell therapies, as well as the cord blood banking business."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
